TRX logo

Tissue Regenix Group Share Price

Symbol: AIM:TRXMarket Cap: UK£27.8mCategory: Pharmaceuticals & Biotech

TRX Share Price Performance

TRX Community Fair Values

    Recent TRX News & Updates

    No updates

    Tissue Regenix Group plc Key Details

    US$28.6m

    Revenue

    US$15.0m

    Cost of Revenue

    US$13.6m

    Gross Profit

    US$14.5m

    Other Expenses

    -US$885.0k

    Earnings

    Last Reported Earnings
    Dec 31, 2024
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    -0.012
    Gross Margin
    47.55%
    Net Profit Margin
    -3.09%
    Debt/Equity Ratio
    36.0%

    Tissue Regenix Group plc Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About TRX

    Founded
    2006
    Employees
    92
    CEO
    Daniel Lee
    WebsiteView website
    www.tissueregenix.com

    Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies for bone graft substitutes, skin, and soft tissue biologics markets in the United States and internationally. The company operates in two segments, dCELL and BioRinse. It offers dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a technology that natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth. The company provides DermaPure, a decellularised dermal allograft that provides soft tissue with supplemental support, reinforcement, and/or protection from mechanical stress. In addition, it offers OrthoPure XT, provides biomechanically appropriate tissue scaffold for cellular repopulation and eventual regeneration; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Further, it provides offers DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks to optimise membrane defects; and sports medicine products. Tissue Regenix Group plc was incorporated in 2006 and is based in Garforth, the United Kingdom.

    U.K. Market Performance

    • 7 Days: 1.6%
    • 3 Months: 7.6%
    • 1 Year: 7.9%
    • Year to Date: 8.1%
    The market has climbed 1.6% in the last 7 days, lead by the Materials sector with a gain of 5.8%. The market is up 7.9% over the last 12 months. Earnings are forecast to grow by 14% annually. Market details ›
    The tide is turning for UK & European markets. Index ETFs won’t cut it since sector spreads are massive. Picking the right companies matters now more than ever.
    Continue reading